Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research

BACKGROUND: Despite the introduction of novel effective treatment regimens like gemcitabine plus nab-paclitaxel and FOLFIRINOX, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive epithelial tumors. Among the genetic alterations frequently found in PDAC, mutations in the KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Baechmann, Sibylle, Ormanns, Steffen, Haas, Michael, Kruger, Stephan, Remold, Anna, Modest, Dominik Paul, Kirchner, Thomas, Jung, Andreas, Werner, Jens, Heinemann, Volker, Boeck, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445280/
https://www.ncbi.nlm.nih.gov/pubmed/28549417
http://dx.doi.org/10.1186/s12885-017-3376-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445280/
https://www.ncbi.nlm.nih.gov/pubmed/28549417
http://dx.doi.org/10.1186/s12885-017-3376-4

Ejemplares similares